Myovant Sciences (Myovant Sciences) Days Payable : 27.24 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Days Payable?

Myovant Sciences's average Accounts Payable for the three months ended in Dec. 2022 was $10.2 Mil. Myovant Sciences's Cost of Goods Sold for the three months ended in Dec. 2022 was $34.2 Mil. Hence, Myovant Sciences's Days Payable for the three months ended in Dec. 2022 was 27.24.

The historical rank and industry rank for Myovant Sciences's Days Payable or its related term are showing as below:

MYOV' s Days Payable Range Over the Past 10 Years
Min: 38.81 Med: 1592.29 Max: 3078.17
Current: 38.81

During the past 7 years, Myovant Sciences's highest Days Payable was 3078.17. The lowest was 38.81. And the median was 1592.29.

MYOV's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 147.375 vs MYOV: 38.81

Myovant Sciences's Days Payable declined from Dec. 2021 (58.04) to Dec. 2022 (27.24). It may suggest that Myovant Sciences accelerated paying its suppliers.

Myovant Sciences Days Payable Historical Data

The historical data trend for Myovant Sciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Days Payable Chart

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Days Payable

Get a 7-Day Free Trial

3,078.17

106.41

Myovant Sciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Days Payable	Get a 7-Day Free Trial															58.04	62.70	43.38	29.63	27.24

Competitive Comparison of Myovant Sciences's Days Payable

For the Biotechnology subindustry, Myovant Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myovant Sciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Days Payable falls into.

Myovant Sciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Myovant Sciences's Days Payable for the fiscal year that ended in Mar. 2022 is calculated as

	Days Payable (A: Mar. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Mar. 2021 )	+	Accounts Payable (A: Mar. 2022 ))	/	count )	/	Cost of Goods Sold (A: Mar. 2022 )	*	Days in Period
=	( (17.809	+	12.25)	/	2 )	/	51.551	*	365
=	15.0295					/	51.551	*	365
=	106.41

Myovant Sciences's Days Payable for the quarter that ended in Dec. 2022 is calculated as:

	Days Payable (Q: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2022 )	+	Accounts Payable (Q: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2022 )	*	Days in Period
=	( (8.215	+	12.217)	/	2 )	/	34.226	*	365 / 4
=	10.216					/	34.226	*	365 / 4
=	27.24

Myovant Sciences Days Payable Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek	director, officer: Principal Executive Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra	officer: Principal Financial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	officer: Principal Fin'l & Accounting	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo	director	ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957